OX2 Therapeutics
Manufacturing · Minnesota, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
16632 Iredale Path, Lakeville, Minnesota...Phone Number
(612) 309-7653Website
www.ox2therapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About OX2 Therapeutics
OX2 Therapeutics is focused on developing innovative therapies to transform cancers into manageable diseases, particularly through the use of peptide ligand checkpoint inhibitors. The company has received FDA approval to conduct clinical trials for its novel peptide, CD200AR-L, aimed at treating high-grade glioblastoma and potentially other solid tumors. Their approach targets the CD200 immune checkpoint to enhance the immune response against tumors, thereby overcoming immunosuppressive barriers. OX2 Therapeutics also aims to extend its technology to veterinary applications, specifically for treating glioma in dogs.Explore more
OX2 Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OX2 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when OX2 Therapeutics launches new products
Click to see if OX2 Therapeutics had a recent Job posting/layoffs
Check if OX2 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
OX2 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if OX2 Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once OX2 Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at OX2 Therapeutics
Earning: See what the market has to say on OX2 Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at OX2 Therapeutics
Find 3 more new buyers
Compare Similar Companies to OX2 Therapeutics
Compare insights from companies similar to OX2 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OX2 Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OX2 Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OX2 Therapeutics.
OX2 Therapeutics Tech Stack
A closer look at the technologies used by OX2 Therapeutics
See more technologies
OX2 Therapeutics News & Media
New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials
MINNEAPOLIS--(BUSINESS WIRE)--OX2 announces today that they treated their first patient in a phase one human trial of a new treatment developed to combat recurrent brain tumors.OX2 Therapeutics receives FDA approval for a Phase I Clinical trial to treat High Grade Glioblastoma
FDA Grants IND Approval to OX2 Tx to Proceed in a Phase I Clinical trial of its Peptide Checkpoint Inhibitor for Patients with Central Nervous System Tumors MINNEAPOLIS, MN, USA, June 8, 2020 /EINPresswire.com/ -- OX2 Therapeutics, Inc, a privately held …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OX2 Therapeutics
Sign Up For FreeTo access detailed company insights
OX2 Therapeutics is focused on developing innovative therapies to transform cancers into manageable diseases, particularly through the use of peptide ligand checkpoint inhibitors. The company has received FDA approval to conduct clinical trials for its novel peptide, CD200AR-L, aimed at treating high-grade glioblastoma and potentially other solid t... Read More
